Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME and PK of AZD2014 in Advanced Solid Malignancies
NCT02640755Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2016
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vistusertib in malignant solid tumor (3 arms), sponsored by AstraZeneca. Primary endpoints: Total Radioactivity in Plasma Following Administration of [14C]-AZD2014, AZD2014 Concentrations in Plasma Following Administration of [14C]-AZD2014 and 23 more. Started Jan 2016; status: completed.
02
Drugs
vistusertib
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT02640755.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02640755.